NCT01962870View on ClinicalTrials.gov

The Role of Vasopressin in the Social Deficits of Autism

PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

May 30, 2017

Study Completion Date

May 30, 2017

Conditions
Autism Spectrum Disorders
Interventions
DRUG

Vasopressin

Participants aged 6 to 9.5 years of age will receive the maximum dose of 24 IU (12 IU twice daily). Participants aged 9.6 to 12 years of age will receive the maximum dose of 32 IU (16 IU twice daily).

DRUG

Placebo

Trial Locations (1)

94305

Stanford University School of Medicine; Psychiatry and Behavioral Sciences, Stanford

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Stanford University

OTHER

NCT01962870 - The Role of Vasopressin in the Social Deficits of Autism | Biotech Hunter | Biotech Hunter